Ad5/35 chimeric oncolytic viruses (OVs) have earlier been shown to increase the level of vector transduction, intratumoral virus spread and survival in a number of xenograft models when compared with Ad5-based viruses. Because radiation and chemotherapy are the current standards of care for most cancer indications, Ad5/35 OVs have been tested here in combination with either radiation or chemotherapy in a head and neck cancer (HNC) xenograft model to determine whether such combination therapies enhance the potency of the virus, thereby leading to a greater therapeutic effect. In mice treated with either Ad5 OV (OV-5) or Ad5/ 35 chimeric OV (OV-5T35H), there was a delay in tumor progression compared with animals treated with phosphate-buffered saline (PBS) alone. When Ad5/35 chimeric OV and radiation were used in combination, there was a further delay in tumor progression, which resulted in a significant increase in the mean survival time of tumor-bearing mice compared with Ad5/35 or Ad5 OV monotherapy or to the combination of Ad5 OV with radiation, which was significantly less potent (Po0.0001) compared with the Ad5/35 OV plus radiation combination. Similarly, a combination of Ad5/35 chimeric OV with cisplatin significantly delayed tumor progression compared with Ad5/35 OV or Ad5 OV virus alone or with the combination of Ad5 virus with cisplatin (Po0.01). In summary, the combination of the potent Ad5/35 chimeric OV with either radiation or chemotherapy leads to significantly increased survival of mice bearing highly aggressive tumors, and may therefore offer an effective treatment strategy for patients with difficult to treat HNC.
Introduction
Radiotherapy and chemotherapy are the current standards of care for localized squamous cell carcinomas of the head and neck (HNC). Nevertheless, loco-regional recurrences occur frequently, 1 and once these tumors recur, they are almost uniformly fatal. Cancer therapy using adenoviral vectors represents a promising alternative to current conventional radiation and chemotherapy treatments. One example of such a virus that has been tested in phase 3 clinical trials for local therapy 2,3 is the replication-defective adenovirus Ad-p53 (Advexin) that expresses the tumor-suppressor protein p53 under the control of the cytomegalovirus promoter. One of the potential shortcomings of replication-defective adenoviruses, however, is the inability of these viruses to spread to uninfected neighboring cells, which may limit their overall antitumor activity. Replication-competent viruses have been designed to replicate selectively in and to lyse tumor cells. 4 The adenoviral vector Addl1520 (ONYX-015), in which the viral E1b 55-kDa gene is deleted, represents one such class of oncolytic viruses (OVs) that has been evaluated alone and in combination with radiation or cisplatin and 5-fluorouracil in phase II clinical trials for the treatment of HNC. Limited efficacy was obtained when Addl1520 was used alone but there was evidence for potential synergistic antitumor activity when combination treatment was used. 5 The limited efficacy of Addl1520 was attributed mainly to the low and variable expression of the Ad5 receptor, coxsackie-adenovirus receptor (CAR), on tumor cells. [6] [7] [8] [9] Furthermore, CAR expression is known to be reduced or lost upon progression of certain tumors to malignancy. 10 Sub-group B adenoviruses such as Ad35, however, use the CD46 receptor for virus binding and entry into cells. 11 Because expression of CD46 is relatively high on tumor cells, 12 a retargeted adenoviral vector that uses CD46 as its cellular receptor may result in increased levels of tumor cell transduction, thereby leading to a potential increase in oncolytic potency.
It has recently been shown that by replacing the Ad5 fiber knob with the Ad35 knob, which recognizes the highly abundant CD46 receptor on tumor cells, viral entry is significantly improved and correlates well with enhanced antitumor activity of Ad5/35 chimeric OVs (OV-5T35H) when compared with Ad5-based OVs (OV-5). 13 In the OVs evaluated in this study, viral E1a gene expression is controlled by the tumor-specific E2F-1 promoter to limit viral replication to tumor cells with defects in the pRb pathway.
14 Evidence from several preclinical and clinical trials suggests that combining replication-competent adenoviruses with standard anticancer treatments such as chemotherapy and radiotherapy can result in a greater therapeutic benefit. 4, [15] [16] [17] [18] Initial dose-finding studies for radiotherapy and chemotherapy were performed in a highly aggressive HNC xenograft mouse model to choose an appropriate dose for these therapies, that is, one that was welltolerated, clinically relevant but showed only modest efficacy when used as monotherapy. The effect of the Ad5/35 OV in combination with the selected dose of either radiation or chemotherapy was subsequently tested in the same model to evaluate whether such combination therapy could enhance the potency of the virus.
The results from these studies show that the combination of OV-5T35H with either radiation or cisplatin significantly improves the survival of mice bearing RPMI2650 head and neck tumor xenografts compared with OV-5T35H or OV-5 monotherapy or to the combination of OV-5 with radiation, and therefore may offer a novel and improved oncolytic therapy for patients with difficult to treat HNC.
Results
Effect of single-dose focused radiation on growth of RPMI2650 tumor xenografts To determine a suitable suboptimal radiation dosage to use in the combination studies, RPMI2650 tumor-bearing mice were treated with a range of radiation doses and the effect on tumor progression was determined. Fractionated radiation doses were tested in the dose-finding pilot studies based on promising clinical data that show that fractionated radiation has an improved safety profile compared with single-dose radiotherapy. 19 The conventional doses of radiation for head and neck squamous cell carcinomas is a once daily dose of 1.8-2.0 Gy given over 30-40 fractions for a total of 70-72 Gy over 7 weeks. 20 Thus, tumor-bearing mice received radiation doses of 2, 5, 10 or 15 Gy, once every other day for a total of three doses (days 1, 3 and 5), which is comparable with the level of radiation that head and neck squamous cell carcinoma patients receive in the clinic. 20 Once the tumors reached a volume of B250 mm 3 , the mice received radiation treatment and tumor progression was determined and compared with a control group that received intratumoral (i.t.) phosphate-buffered saline (PBS) injections (Supplementary Figure 1a ).
Mice treated with the highest doses of either 10 Gy or 15 Gy showed a significant body weight loss (420%) and had to be euthanized within 1 week. Mice treated with doses of 2 Gy or 5 Gy showed an initial body weight loss but recovered after completion of the radiation treatment (Supplemental Figure 1b) . No significant body weight loss was observed in the PBS-injected mice. A dose-dependent antitumor effect was observed with the doses used in this study, with mice treated with 2 Gy showing a delay in tumor progression when compared with the PBS-treated control mice (Po0.01). In animals treated with 5 Gy of radiation, only minimal tumor progression was observed for up to 35 days post-treatment (Po0.0001), suggesting that, as expected, the higher the radiation dose, the better the antitumor efficacy. A dose of 3.3 Gy, between the two lowest doses tested, was selected for the combination studies reported here, as it was expected to have only modest effects on tumor progression when used as monotherapy but is still a clinically relevant dose of radiation. 20 Combination of Ad5/35 chimeric OVs with radiation treatment leads to significantly increased survival of mice bearing highly aggressive RPMI2650 HNC tumors. To determine whether the combination of radiation with oncolytic adenoviruses would result in improved antitumor efficacy, both Ad5 and Ad5/35 OVs (OV-5 and OV-5T35H) were tested in a highly aggressive HNC xenograft model (Figure 1 ). Treatment was initiated in nude mice bearing subcutaneous (s.c.) RPMI2650 tumor xenografts when tumors reached B250 mm 3 . Mice received i.t. injections of either OV-5 alone, OV-5T35H alone (1 Â 10 10 viral particles (v.p.) or PBS on days 1, 3, 5 and 7 or radiation therapy alone (3.3 Gy per dose) on days 1, 3 and 5. Mice treated with the combination received the virus on days 1, 3, 5 and 7, followed by fractionated radiation therapy on days 9, 11 and 13. Mice that received radiation only were treated at the same time as animals that received virus only to keep tumor sizes similar at the initiation of treatment. Tumor growth and survival of animals were monitored over time.
In the PBS-treated control group, the tumors progressed steadily and the tumor volume increased by 13-fold over a period of 35 days (Figure 1a) . Compared with animals injected with PBS, there was a significant delay of tumor progression in mice treated with either monotherapy consisting of OV therapy or radiation therapy or with a combination of both therapies (Po0.0001). In the OV-5-or radiation-treated mice, the tumor volume increased by 7.8-fold. In the OV-5T35H-treated group, there was a significant delay in tumor progression that resulted in a 5.7-fold increase in tumor volume during the same time period. (OV-5T35H vs OV-5 or radiation; Po0.01).
When OV-5 virus was combined with radiation, reduced tumor progression was observed compared with either virus or radiation therapy alone and the combination resulted in only a 5.9-fold increase in tumor volume, about the same as in animals treated with OV-5T35H as monotherapy. When mice were treated with both OV-5T35H and radiation, there was a significant delay in tumor progression when compared with the OV-5T35H-treated group (Po0.0001) or to the OV-5-and radiation-treated group (Po0.0001), with overall minimal tumor progression resulting in a modest 1.8-fold increase in tumor volume by day 35.
To evaluate whether the improved efficacy of combination treatment in controlling tumor progression translated into improved survival, treated mice were monitored until tumor volumes reached 2000 mm 3 , at which point they were euthanized (Figure 1b) . PBS-injected animals had a mean survival time (MST) of 34 days with no animals alive by day 42, whereas mice treated with either OV-5, OV-5T35H or radiation as monotherapy had a significant improvement in survival with MST values ranging from 51.5 to 56 days (Po0.01). A further significant improvement in survival was observed in mice treated with the combination of OV-5T35H and radiation, which has a MST of 84 days (Po0.01), compared with mice treated with any of the other therapies. Mice that were treated with OV-5 in combination with radiation did not show a similar survival advantage (MST ¼ 60 days). These survival data showed that the combination of fiber chimeric OV with radiation therapy produced greater antitumor efficacy, and improved survival of treated animals compared with animals treated with either virus or radiation therapy alone or with the combination of OV-5 with radiation.
Radiation-induced tumor cell death impacts virus production within the tumor To evaluate the in vivo effects of radiation on viral replication, the number of hexon-positive cells and infectious v.p. within the tumors after virus administration and radiation therapy were determined. Tumors were harvested on days 14 and 28 after initiation of therapy and half of the tumor was used to quantify infectious v.p. by titering tumor homogenates on AE1-2a cells (Figure 2a) . 13, 21, 22 The other halves of the tumors were analyzed by immunohistochemistry for the presence of hexon protein to determine the extent of virus spread throughout the tumors. Qualitative assessment of tissue sections for hexon-positive cells in tumors (at Â 5 magnification) revealed that on day 14 tumors treated with the OV-5T35H virus as monotherapy or in combination with radiation had higher numbers of hexon-positive cells To verify that the increased number of hexon-positive cells observed in tumors treated with OV-5T35H compared with OV-5 were because of increased virus spread and replication, total infectious v.p. within the tumors were determined by titering tumor homogenates on AE1-2a cells as described earlier. 13 Higher titers of infectious virus were observed at both time points with OV-5T35H compared with OV-5, suggesting a greater level of i.t. virus replication and spread of the chimeric vector ( Figure 2a ). This increase in virus titer is potentially because of the higher CD46 than CAR receptor levels on tumor cells 10, 12, 13 that allow better transduction of tumor cells by the chimeric vector, compared with the Ad5-based vector, leading to improved virus replication and spread.
The effect of single-dose radiation on CD46 receptor levels in RPMI2650 cells in vitro showed a modest increase in CD46 levels that was dose dependant (data not shown). However, in animals treated with either OV-5 To investigate this further, sections of tumors collected on day 28 were stained for caspase 3, a marker for apoptosis. Visual analyses (at Â 5 magnification) revealed the presence of higher numbers of apoptotic cells in tumors that had been treated with radiotherapy compared with untreated or virus only treated tumors (Figure 2c ). Only few apoptotic cells were found in tumors of mice that had not received radiotherapy. This suggested that radiation-mediated apoptosis in the tumors, which ultimately reduced virus production, was because of host tumor cell killing.
Effect of cisplatin chemotherapy on RPMI2650 tumor growth To determine a suboptimal dose of cisplatin that produced only a modest delay in tumor progression as monotherapy, a dose-finding study was performed in which RPMI2650 tumor-bearing animals were treated with a range of cisplatin doses and the effect on tumor growth and treatment-related toxicity were determined. Once the tumors reached a volume of B250 mm 3 , tumorbearing mice received i.p. (intraperitoneal) doses of 1, 3 or 5 mg kg À1 of cisplatin, given once every other day for a total of 5 days; control animals received only PBS. Tumor volumes and body weights were monitored over time (Supplementary Figure 2a) .
Mice treated with the highest cisplatin dose (5 mg kg À1 ) showed a significant loss of body weight (420%) and had to be euthanized within a week. Mice receiving 3 mg kg
À1
of cisplatin showed initial body weight loss but recovered once the treatment was finished (Supplementary Figure  2b) . No significant body weight losses were observed in animals treated with either 1 mg kg À1 or with PBS. A delay in tumor progression compared with the PBSinjected animals was observed with either 1 or 3 mg kg À1 with only minimal toxicity. A suboptimal, well-tolerated dose of 2 mg kg À1 of cisplatin was selected for the combination studies to produce only modest antitumor efficacy when used as monotherapy, while leaving a window for observation of additive or synergistic effects of the virus in animals treated with the combination therapy.
Ad5/35 chimeric oncolytic virus in combination with cisplatin leads to survival advantage of RPMI2650 tumor-bearing mice To determine whether the combination of cisplatin with oncolytic adenovirus would result in enhanced antitumor efficacy, mice bearing s.c. RPMI2650 xenograft tumors were injected with either OV-5 or OV-5T35H, alone or in combination with 2 mg kg À1 of cisplatin treatment that was initiated in the tumor-bearing mice (n ¼ (Figure 3) .
In the PBS-injected control group, there was steady growth of the tumors, which reached an average volume of approximately 1660 mm 3 at 27 days post-initiation of PBS injections. In contrast, in the groups treated with either virus alone, with cisplatin alone or with the combination of either virus with cisplatin, there was a significant delay in tumor progression (virus or cisplatintreated groups vs PBS, Po0.0001; Figure 3a The greatest delay in tumor progression was observed in animals treated with OV-5T35H in combination with cisplatin. In this group, the average tumor volume was 440 mm 3 at 27 days post-initiation of virus treatment, significantly lower than that seen after treatment with OV-5 plus cisplatin (610 mm 3 ; Po0.01) (Figure 3a ). To evaluate whether the reduced tumor progression seen in the combination treatment groups translated into improved survival, treated mice were monitored until tumor volumes reached 42000 mm 3 , at which point they were euthanized (Figure 3b ). Animals injected with PBS alone had a MST of 30 days with no animals alive by day 35. Only a slight increase in survival time was seen in mice treated with OV-5 alone (MST ¼ 32 days) and a significant increase in the survival time was observed in mice treated with OV-5T35H alone (MST ¼ 42 days, Po0.01), showing the increased potency of the chimeric vector compared with the Ad5-based virus in this HNC xenograft model. Animals treated with virus plus cisplatin exhibited prolonged survival compared with the animals treated with either cisplatin or virus alone. The greatest improvement in survival was observed in mice treated with the combination of OV-5T35H and cisplatin (MST ¼ 47 days), which was significantly greater (Po0.01) than the MST in animals treated with OV-5T35H alone or with the combination of OV-5 and cisplatin (43.5 days and 42 days, respectively). These survival data showed that cisplatin enhanced the antitumor efficacy of the chimeric OVs.
Virus replication is not altered by cisplatin chemotherapy in RPMI2650 tumor-bearing mice To determine whether chemotherapy with cisplatin affected virus replication, the number of hexon-positive cells and infectious v.p. within the tumors were determined, as outlined above. Tumors were harvested on days 14 and 28 after treatment and a portion of the tumor was used to quantify infectious v.p. by titering tumor homogenates on AE1-2a cells (Figure 4a) . No significant difference in the level of infectious virus was found in tumors of animals treated with either virus alone or with virus plus chemotherapy on either day 21 or day 28 post-initiation of virus treatment. This suggested that cisplatin chemotherapy did not detectably affect virus replication in this model.
At both time points, however, there was a 5-10-fold lower titer of infectious virus in the tumors treated with OV-5 alone or OV-5 with cisplatin compared with the tumors treated with OV-5T35H alone or OV-5T35H with cisplatin. This again confirmed that the chimeric virus replicated more efficiently and had higher i.t. virus production than the Ad5 parental virus in this tumor model. Immunohistochemical staining for hexon and caspase 3 were performed to evaluate the extent of virus replication and cisplatin-mediated apoptosis further. An increase in hexon-positive cells was found in tumors of mice treated with OV-5T35H alone or OV-5T35H plus cisplatin compared with those treated with OV-5 alone or OV-5 and cisplatin (Figure 4b ), supporting the earlier reports that showed an increase in infectious virus titer in the OV-5T35H-treated groups compared with OV-5-treated groups.
In addition, there was no difference in the number of apoptotic cells found in the tumors treated with either virus alone or virus with cisplatin at days 14 and 28 (data not shown). Visual evaluation of tumor sections, showed that the apoptotic cells present within the tumors of animals treated with the combination therapy appeared to be increased at the end of the study (day 52, data not shown), suggesting that cisplatinmediated apoptosis occurred in tumors at later time points. 
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Discussion
Head and neck cancer is routinely treated in the clinic with either radiation or various chemotherapies, 23 but with only limited success in advanced stage disease. 15 In the studies described here, Ad5/35 fiber chimeric OVs have been tested in combination with radiation or chemotherapy to determine the effectiveness of such combinations in the treatment of HNC tumors. Earlier studies have shown that the combination of oncolytic adenoviruses with standard therapy may be more effective in controlling tumor growth than treatment with an OV alone. 17 The limited efficacy reported earlier with Ad5-based OVs in solid tumors has been attributed primarily to the low and variable expression of CAR, the Ad5 virus receptor, on cancer cells [6] [7] [8] [9] and to the loss of expression upon progression of some tumors to malignancy. 10 By replacing the Ad5 fiber knob with the Ad35 knob, which recognizes the highly abundant and widely expressed CD46 receptor on tumor cells, viral entry is significantly improved, correlating well with enhanced antitumor efficacy of Ad5/35 chimeric viruses when compared with Ad5-based viruses. 13 The improved efficacy observed with Ad5/35 chimeric virus in this study may potentially be because of increased CD46 receptor levels that were observed in vitro after single-dose radiation treatment allowing a greater spread of virus from cell to cell. Earlier studies have shown that radiation treatment did not affect CD46 receptor levels in radiation-resistant glioma cells suggesting that the effect observed could be dependent on the tumor cell lines tested. 21 In addition, the combination of virus and radiation did not lead to an increase in virus spread within the tumor suggesting that the increase in CD46 receptor levels observed in vitro may not be present in vivo or if present to a lower extent. The fact that the radiation was given as a single dose in the in vitro studies compared with the fractionated doses received in the in vivo studies may also account for the differences observed. Interestingly, studies have also shown that the combination of radiation with Ad5-based vectors can improve gene transfer but that the CAR receptor levels measured in vitro did not increase after radiation treatment 22 suggesting that the impact of radiation on receptor levels measured in vitro and in vivo may differ.
To determine whether the chimeric viruses in combination with standard therapy for HNC would have increased antitumor efficacy, animals bearing RPMI2650 HNC xenograft tumors were treated with either chimeric or Ad5 virus with or without radiation (3. ). When used as monotherapy, these dose levels of radiation and cisplatin provide only modest antitumor activity, but have minimal toxicity.
In the studies reported here, the highly infectious OV-5T35H shows significantly enhanced antitumor efficacy and delayed tumor progression compared with the OV-5 virus (Po0.01). When tumor-bearing animals are treated with either the Ad5 or Ad5/35 OVs in combination with radiation or cisplatin, the efficacy of both viruses in delaying initial tumor progression is significantly improved compared with the corresponding virus alone. In addition, when the potent OV-5T35H chimeric virus is combined with either radiation or cisplatin, the resultant effects are additive, and significantly better than any of the monotherapy treatments or the combination treatment of OV-5 with radiation or chemotherapy (Po0.01).
The improved efficacy and delay in tumor progression observed with the combination of OV-5T35H and radiation or cisplatin also results in improved survival times for the tumor-bearing animals. Interestingly, even though there are enhanced antitumor effects in mice treated with virus in combination with radiation compared with treatment with virus alone, there are no detectable increases in virus replication or spread within the tumors, as indicated by the amount of infectious virus and the number of hexon-positive cells detected on day 14. These data suggest that the improved antitumor efficacy seen in this model when radiation is combined with chimeric vectors is not because of an increase in virus replication but because of improved cell killing by the combination treatment compared with that when either vector or radiation is used as a monotherapy. This improvement in cell killing is probably because of radiosensitization of the cells by a neoadjuvant effect of the OV that has been observed earlier with oncolytic adenovirus in combination with radiation. 24 Nevertheless, by day 28 there is a decrease in the titer of infectious virus detected in tumors treated with both virus and radiation compared with the level detected in tumors treated with virus alone. The presence of increased apoptotic cells, as indicated by caspase 3 staining in the tumors treated with radiation at day 28, suggests that the number of cells capable of efficiently replicating the virus is reduced and this results in a lower overall yield of infectious virus.
In addition, damage to the tumor microvasculature such as intravascular thrombosis, which also seems to play an important role in the response to radiation 17 can result in an increase in necrotic areas within the tumor that may result in a reduction of effective viral spread within the tumor. Thus, the increased number of apoptotic cells and the level of necrosis in tumors treated with radiation at later time points may explain the lower infectious titers observed. Nevertheless, the combination of tumor cell death induced by the different mechanisms used by OV and radiation results in additive antitumor efficacy during radiation combination therapy, and an overall increase in potency of the combination treatment.
Oncolytic virotherapy has earlier shown promising results in combination with chemotherapy in preclinical models. 5, [15] [16] [17] The addition of the OVs appears to increase tumor killing significantly when added to a standard chemotherapy treatment. As observed with the radiation combination, the combination of the potent OV-5T35H chimeric virus with cisplatin is superior to either treatment alone and to the combination of OV-5 with cisplatin.
As noted above for the radiation treatment, the enhanced antitumor efficacy observed with the cisplatin combination is not due to increased virus replication, as indicated by comparable levels of hexon-positive cells and infectious titers in tumors treated with either virus alone or in combination with cisplatin. This suggests that the combination of either radiation or cisplatin with OV results in an additive effect on the delay in tumor growth because neither radiation nor cisplatin treatment results in increased virus production, a result that would be expected if the combined effects are synergistic.
In contrast to the radiation combination study, the viral titer and number of hexon-positive cells on days 21 and 28 are almost identical after treatment with virus alone or in combination with cisplatin. This suggests that viral replication is not adversely affected by cisplatin treatment. Although there are no differences in the number of apoptotic cells present at the early time points, there are increased numbers of apoptotic cells in the tumors treated with virus and cisplatin at the end of the study, which suggests that the low dose of cisplatin used here may require more time to induce cell death in this model.
One major advantage of combining OV treatments with radiation or chemotherapy is that lower doses of radiation or chemotherapeutic agent may be required to obtain a beneficial therapeutic effect, and with a concomitant reduction in the level of the adverse side effects normally associated with these treatment modalities. Combination therapy using OVs and cytotoxic agents that have different mechanisms of action is therefore an attractive approach to treat highly aggressive HNC and other cancers.
In summary, the combination of the potent Ad5/35 chimeric OV with radiation or chemotherapy leads to significantly increased survival of mice bearing highly aggressive tumors and may therefore offer an effective treatment strategy for patients with difficult to treat HNC.
Materials and methods
Oncolytic viruses
OV-5 and OV-5T35H are replication-competent adenoviruses that have been engineered to replicate selectively in tumor cells. 13 In these viruses, the tumor-specific E2F-1 promoter replaces the native E1a promoter to restrict viral replication to cells having defects in the pRb pathway.
14 In addition, the cDNA encoding human granulocyte-macrophage colony-stimulating factor replaces the open reading frame encoding the non-essential 19-kDa glycoprotein in the E3 region. Human granulo-cyte-macrophage colony-stimulating factor is a cytokine that recruits and activates dendritic cells that are essential antigen-presenting cells for immune activation. However, human granulocyte-macrophage colony-stimulating factor is not functional in mice due to its species specificity and therefore it has no effect in murine tumor studies, especially when studies are performed in immunodeficient mice as these studies were. With the aim of improving viral entry and spread throughout the tumor, the Ad5 fiber knob of OV-5 has been replaced with the Ad35 knob to generate OV-5T35H. 13 
Tumor cells
The human HNC cell line, RPMI2650 (CCL-30) and the human melanoma, A375 (CRL-1619) were purchased from American Type Culture Collection (ATCC, Manassas, VA). The cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.
In vivo efficacy studies Female NCR (nu/nu) mice (4-6 weeks of age; body weight 18-20 g) were purchased from Simonsen Laboratories (Gilroy, CA). Mice received an s.c. injection of 5 Â 10 6 RPMI2650 cells with an equal volume of matrigel (injection volume of 200 ml) into the right flank. Viral treatment was initiated when tumors reached a mean tumor volume of B250 mm 3 , as determined using the formula: Volume ¼ W Â (L) 2 /2; where W is the tumor width and L is the length, in millimeters. 13 For the dose-finding studies, tumor-bearing animals were randomly distributed into treatment groups (n ¼ 5). In the radiation treatment pilot study, animals were irradiated at doses ranging from 2 to 15 Gy, every other day for 3 days. Before irradiation, mice were anesthetized by i.p. injection with ketamine and xylazine. Irradiation of the tumor site was performed using a 137 Cs irradiator (Shepherd Mark-I Model 30, SN 1095 at CGI). A Collimator with a 10 mm collimation window was used to shield the animals so that only the tumor was irradiated. The mice were secured in position in Lucite mouse holders using Velcro and the holders attached to the collimator using screws. In the cisplatin pilot study, additional groups of animals were injected i.p. with cisplatin at doses ranging from 1 to 10 mg kg À1 , every other day for 5 days. All tumor volumes were determined over time using the formula presented above. Radiation and cisplatin doses and treatment sequence used in the pilot studies were selected based on published data 5, 16, 17 In the single-treatment studies, mice bearing s.c. HNC xenografts (n ¼ 16) received 1 Â 10 10 v.p. of either OV-5 or OV-5T35H, or PBS alone (50 ml per injection), i.t. on days 1, 3, 5 and 7, or radiation therapy alone (3.3 Gy per dose) on days 1, 3 and 5, or combination therapy. The virus treatment was given first in the combination studies, on days 1, 3, 5 and 7, followed by radiation therapy on days 9, 11 and 13.
In the chemotherapy studies, mice with s.c. HNC xenografts (n ¼ 16) in the single-treatment groups received 1 Â 10 10 v.p. of either OV-5, OV-5T35H or PBS alone (50 ml per injection, i.t.) on days 1, 3, 5 and 7, or cisplatin alone at 2 mg kg À1 (100 ml per injection, i.p.) on days 1, 3, 5, 7 and 9 or combination therapy. In the combination treatment, mice (n ¼ 12) received virus treatment on days 1, 3, 5 and 7, followed by cisplatin treatments on days 9, 11, 13, 15 and 17. Tumor volume between different groups was compared by linear regression analysis. Survival times of mice from different groups were compared by Kaplan-Meier analysis.
Selected animals from each group (n ¼ 3) were sacrificed at various time points and tumors were collected. Tumors were analyzed by immunohistochemistry for the presence of hexon protein to determine the extent of virus spread throughout tumors. Tumor sections were qualitatively evaluated for the extent of hexon-positive cells without enumerating the positive cells (at Â 5 magnification). To verify whether increased numbers of hexonpositive cells was due to increased virus spread and replication, total infectious v.p. within tumors were quantified by titering tumor homogenates on AE1-2a cells as described earlier. 25, 26 The infectious titers were presented per mg protein, to normalize for tumor size. For histological analyses, 5-mm paraffin embedded tumor sections were stained for hexon protein using the Zymed Histomouse kit (Carpenteria, CA) according to the manufacturer's instructions. The remaining half of the tumor was used to isolate virus and the virus titer was determined by infecting AE1-2a cells with the extracted virus. The presence of apoptotic cells within tumor sections was determined using a rabbit anti-human/mouse active caspase 3 antibody (R&D Systems, Minneapolis, MN). Antigen retrieval consisted of steaming slides in high pH (9) EDTA solution (DAKO Cytomation, Carpinteria, CA). Caspase 3 was detected using a biotinylated goat anti-rabbit secondary antibody (DAKO Cytomation) that was coupled with streptavidin HRP (Jackson Immunologicals, West Grove, PA) and developed with DAB chromogen (DAKO). The extent of apoptosis throughout tumor sections was qualitatively evaluated (at Â 5 magnification).
